| Serial Number | 98089376 |
| Word Mark | IMMUNOVX |
| Filing Date | Tuesday, July 18, 2023 |
| Status | 748 - STATEMENT OF USE - TO EXAMINER |
| Status Date | Monday, March 2, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, February 11, 2025 |
| Goods and Services | Clinical research in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Research and development and consultation related thereto in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development of new products; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research and development of vaccines and medicines; Research and development services in the field of antibodies; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific research; Scientific research consulting; Basic and clinical research in the field of respiratory science and medicine; Biochemical research and development; Consulting services for others in the field of design, planning, and implementation project management of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Medical and scientific research in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Medical and scientific research, namely, conducting clinical trials for others; Pharmaceutical research and development; Product research and development; Providing information about medical and scientific research; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Scientific research and development; Scientific research in the nature of conducting clinical trials for others in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, August 16, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | Sunday, July 23, 2023 |
| First Use In Commerce Date | Sunday, July 23, 2023 |
| Party Name | NOT AVAILABLE |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 01 - Individual |
| Address | Bethlehem, PA 18015 US |
| Party Name | NOT AVAILABLE |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 01 - Individual |
| Address | Conshohocken, PA 19428 US |
| Event Date | Event Description |
| Friday, July 21, 2023 | NEW APPLICATION ENTERED |
| Wednesday, August 16, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Saturday, March 23, 2024 | ASSIGNED TO EXAMINER |
| Saturday, March 23, 2024 | NON-FINAL ACTION WRITTEN |
| Saturday, March 23, 2024 | NON-FINAL ACTION E-MAILED |
| Saturday, March 23, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, May 10, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, September 20, 2024 | ASSIGNED TO LIE |
| Friday, September 20, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, September 20, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, October 17, 2024 | FINAL REFUSAL WRITTEN |
| Thursday, October 17, 2024 | FINAL REFUSAL E-MAILED |
| Thursday, October 17, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Friday, January 17, 2025 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Friday, January 17, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, January 17, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, January 20, 2025 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Monday, January 20, 2025 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Monday, January 20, 2025 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Monday, January 20, 2025 | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
| Tuesday, January 21, 2025 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Wednesday, January 22, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, February 5, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, February 11, 2025 | PUBLISHED FOR OPPOSITION |
| Tuesday, February 11, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, April 8, 2025 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Monday, August 25, 2025 | TEAS STATEMENT OF USE RECEIVED |
| Saturday, February 28, 2026 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Monday, August 25, 2025 | USE AMENDMENT FILED |
| Monday, March 2, 2026 | STATEMENT OF USE PROCESSING COMPLETE |